Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.
Wenxin Xu, Brian I Rini, Laurence Albiges et al.
✦ AI-curated · Sources linked
In 30 seconds
This matched-sample analysis within the randomised IMmotion010 trial examined genomic and transcriptomic differences between primary and recurrent tumours in high-risk localized renal cell carcinoma. Analyses included transcriptomic data from 80 matched pairs and genomic data from 52. Compared with published metastatic cohorts, primary tumours had more angiogenic and small nucleolar RNA signatures and fewer T-effector/proliferative and stromal/proliferative signatures. Recurrent tumours showed increased proliferation-, fatty acid synthesis-, and stromal-related signatures. Recurrences after atezolizumab also showed reduced MHC-I expression, a finding the authors say requires clinical validation.
Key findings
- Matched transcriptomic analyses included 80 primary–recurrence pairs; matched genomic analyses included 52.
- Recurrent sites showed upregulation of signatures related to cell proliferation, fatty acid synthesis, and stromal biology, including matrix and fibroblasts.
- Placebo-arm recurrences had increased B cell and macrophage signatures, whereas recurrences after atezolizumab showed downregulation of MHC-I.
Why it matters
The findings suggest that recurrent tumours may have molecular features distinct from their primary tumours, and that some features may differ according to adjuvant treatment received. Such differences could inform biological understanding of recurrence and provide hypotheses for subsequent treatment research, while the reported signatures do not establish treatment benefit or guide individual decisions.
What to keep in mind
The matched analyses were limited to 80 transcriptomic and 52 genomic pairs. The authors state that the MHC-I finding requires further clinical validation.